Characterization of a 3D matrix bioreactor for scaled production of human mesenchymal stem cells
January 15-19, 2017
Human Mesenchymal Stem Cells (hMSCs) are multipotent, immune-privileged, and possess the capacity to proliferate ex-vivo, making them a good candidate for stem cell therapy. However, a reliable scalable production system for hMSCs is needed to fuel the growing field of regenerative medicine. Current growth of hMSCs is achieved through adherent 2D methods using tissue culture flasks or cell factory systems. These processes are labor intensive and can lead to low purity and poor yield of hMSCs due to the limited control of culture conditions inherent in these systems. In this work, we are investigating a novel 3D honeycomb matrix culture system for controlled high density hMSC production. We have assessed compatibility of the hMSCs on the honeycomb matrix and developed a scale down model bioreactor for development and characterization. Computational Fluid Dynamic (CFD) modeling is used in parallel with the described in-vitro experimentation to characterize shear profiles and oxygen transport for optimization of the conditions to support high cell density hMSC cultures. These techniques will potentially allow for higher yield and purity of hMSCs to meet the large quantities of cells needed for emerging whole cell therapies.
Andrew B. Burns, Corinna Doris, Kevin Vehar, Cameron Bardliving, M. Ian Phillips, and Parviz Shamlou, "Characterization of a 3D matrix bioreactor for scaled production of human mesenchymal stem cells" in "Scale-up and Manufacturing of Cell-based Therapies V", Tom Brieva, Celgene Cellular Therapeutics William Miller, Northwestern University Chris Mason, University College London Eds, ECI Symposium Series, (2017). https://dc.engconfintl.org/cellbasedtherapies_v/69